Sanofi terminates Phase III CIPD trial due to low efficacy

While Sanofi’s study of riliprubart in CIPD has been terminated, another study will continue. While Sanofi’s study of riliprubart in CIPD has been terminated, another study will continue. This decision follows an interim analysis by an independent data monitoring committee (IDMC). Credit: Piotr Swat/Shutterstock.com. Sanofi is terminating a Phase III chronic inflammatory demyelinating polyneuropathy (CIDP) trial of riliprubart after analysis showed the drug is unlikely to show efficacy. The Phase III MOBILIZE study (NCT06290128) investigated the IgG4 humanised monoclonal antibody (mAb) in patients with CIDP refractory to standard-of-care (SoC). SoC includes corticosteroids. Clinical Trials Real World Evidence Reports Systemic…

Source: Clinical Trials Arena